Biotechnology

#Biomedical research #Biotechnology #Drug discovery #Heart disease #mRNA-based vaccines

This week in Drug Discovery (13 – 17 July) 

News round-up for 13 – 17 July by Bruno Quinney, Content Team at DDW.  This week, a new drug has shown potential to treat heart disease. Elsewhere, Cancer Research UK is leading a global cancer trial.  The top stories:  New drug could treat common heart disease, study… Read More

#News

#Biotechnology #Europe #Funding #Venture funds

European biotech venture builder Kurma closes €215m fund

Kurma Partners, a European healthcare venture capital firm, has announced the final closing of Biofund IV at €215 million.   The new fund will support the discovery and development of disruptive therapeutic solutions for severe or incurable diseases.   Building on the €160 million Biofund III, this successful fundraise has increased the… Read More

#Business & Investment #News

#Autoimmune disease #Biotechnology #Inflammatory diseases

Laigo Bio announces new CSO as part of board appointments 

Biotechnology company Laigo Bio has appointed Dr Richard Sainson as Chief Scientific Officer as part of a swathe of board appointments.  The company, which specialises in autoimmune and inflammatory diseases, says Sainson will lead scientific strategy and oversee the advancement of Laigo’s proprietary SureTACs platform and programmes towards the clinic.   Sainson has over 25… Read More

#News

EU flag
#Biotechnology #Business #Europe #Regulatory

Successfully navigating the EU pharma package without the big pharma overhead

Cem Zorlular, CEO of Er-Kim, explains how biotech can turn the new EU pharma package from challenge to opportunity.  In 2028, when new legislation takes effect, the European pharmaceutical landscape will undergo its most significant transformation in two decades. For biotechs, the new EU pharma package is not just a… Read More

#Business & Investment #Exclusive Content

Scientist in laboratory
#Biotechnology #Cancer research #Clinical trial

First patient dosed in trial of MTHFD1/2 inhibitor  

The first patient has been dosed in the Phase I/II clinical trial of a MTHFD1/2 inhibitor to treat advanced solid tumours, biotechnology company One-carbon Therapeutics has announced.  TH9619, a first-in-class, potent, small-molecule, and a dual inhibitor of MTHFD1/2. TH9619 kills cancer cells via a dual mechanism of… Read More

#News

Deal making concept
#Biomarkers #Biotechnology #Drug development

Mursla Bio partners with pharma company on drug development 

Biotechnology company Mursla Bio has announced a partnership with a pharma company to advance biomarker-guided drug development.  While the company has not been named, Mursla Bio says it is a global pharma leader recognised for its expertise in biomarker-guided precision medicine in metabolic dysfunction-associated steatohepatitis (MASH).  Under the collaboration, Mursla… Read More

#Business & Investment #News

#Biotechnology

Slingshot Therapeutics announces board appointments

Biotechnology company Slingshot Therapeutics, part of the Syncona Accelerator, has appointed John Isaac as Chief Scientific Officer and Bobby Soni as Chief Business Officer.  Isaacs will be responsible for the company’s scientific strategy, progress across the pipeline, and delivery of therapeutic assets. He will also lead the identification, technical assessment and selection of early-stage drug… Read More

#News

Japanese flag
#BioIndustry Association #Biotechnology #Collaboration #Japan Bioindustry Association

UK and Japan partner to advance biotech

The UK BioIndustry Association (BIA) and Japan Bioindustry Association (JBA) have signed a deal that aims to connect the two countries’ life sciences and biotech sectors to advance medical innovation and commercialise engineered biology. The countries memorandum of understanding (MOU) aims to establish new links between British and Japanese biotech… Read More

#Business & Investment #News

UK and US flags
#Artificial intelligence (AI) #Biotechnology #Drug discovery #UK #United States

What does the US-UK tech partnership mean for AI drug discovery?

The recent state visit to the UK by US President Trump was accompanied by the unveiling of a ‘US-UK tech partnership’ on 16 September. DDW speaks to experts at MHA’s life science team, who advise biotechnology and pharma firms in both the UK and US, on what this means for… Read More

#Exclusive Content

GBP pound sterling funding
#Biotechnology #Financing #Fundraising #Oncology

Trogenix secures £70m to advance oncology pipeline

Biotech company Trogenix has secured £70 million ($95 million) in funding to help advance its pipeline of cancer therapies.   The Series A funding was led by IQ Capital and invested in by 4BIO Capital, alongside new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital. The round also included… Read More

#Business & Investment #News

#Alys Pharmaceuticals #Atopic dermatitis #Biotechnology #Cold Urticaria #Dermatology #Drug discovery #Mastocytosis #Seed funding #Systemic mastocytosis

New podcast: First-in-class mechanisms for the next wave of dermatology innovation

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Thibaud Portal, Founder… Read More

#News

Molecular,Model,Of,Antibody
#Antibody drug conjugate (ADC) #Biotechnology

Synaffix and Qurient Therapeutics reach agreement to develop ADCs

Biotechnology company Synaffix has announced it has entered a licensing agreement with biopharmaceutical company Qurient Therapeutics for the development of a dual-payload antibody-drug conjugates (ADCs).  Dual-payload ADCs are designed to deliver two separate cytotoxic agents with distinct mechanisms of action to target cancer cells, aiming to enhance therapeutic efficacy and… Read More

#Business & Investment #News

#Amyotrophic lateral sclerosis (ALS) #Biotechnology #Blood-based biomarkers #MND #PLL Therapeutics

Unlocking early detection and treatment of ALS

PLL Therapeutics will present its strategic approach in the early detection and treatment of Amyotrophic Lateral Sclerosis (ALS), a form of motor neuron disease (MND), at the 19th Bioshares Biotech Summit. Bioshares is an Australian biotech stock report. The summit, hosting emerging life science companies listed on the ASX, with… Read More

#News

Human neuron
#Age-related diseases (ARDs) #Artificial intelligence (AI) #Biochemistry #Biotechnology #Integrated Biosciences #Neuroscience #Optogenetics

New optogenetic screening platform for drug discovery

Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases, has published a study in Cell, introducing its optogenetic screening platform. According to the paper, the platform allows for precise and dynamic control of biological targets and processes, unlocking a powerful new… Read More

#News

#Artificial intelligence (AI) #Biopharma #Biotechnology #Drug discovery #Genetics / genomics

DDW Summer edition – out now!

The DDW Summer issue is available to read now. It features in-depth articles on the technologies and advancements driving genomics drug discovery, how supercomputing can drive neuroscience discoveries, and everything you need to know about spatial biology.  Other features include:   A market report on… Read More

#Editor's Choice #News